Background Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, pregnancy ...
Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...
Pregnancy increases the risk of flare in patients with SLE and is associated with excess fetal morbidity and mortality.1 The ...
An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more ...
Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...
22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...
Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
Introduction Anifrolumab (Saphnelo) is approved for adult patients with moderate-severe systemic lupus erythematosus (SLE). Considering its commercialisation in Spain in 2023, observational studies ...
The British Isles Lupus Assessment Group (BILAG)-2004 index is a comprehensive disease activity instrument for systemic lupus erythematosus (SLE). 1 Its key advantages are the ability to capture rare ...
Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by persistent damage to multiple organs and tissues, including the skin, kidneys, cardiovascular system, and brain.
Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback